Treatment of central retinal vein occlusion with triamcinolone acetonide: An optical coherence tomography study

Seminars in Ophthalmology

Volumn 18, Issue 2, 2003, Pages 67-73

  Ip, Michael ^a   Kahana, Alon ^a   Altaweel, Michael ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Central retinal vein occlusion; CRVO; Intravitreal steroid injection; Macular edema; OCT; Optical coherence tomography; Triamcinolone; Vitreous, venous occlusion

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; AGED; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FOLLOW UP; GLAUCOMA; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA EDEMA; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; EDEMA; FEMALE; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULA LUTEA; MALE; MIDDLE AGED; RETINAL DISEASES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 0043239239     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.1076/soph.18.2.67.15860     Document Type: Review

References (36)

1. Klein ML, Finkelstein D. Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol. 1989;107:1297-1302.
2. Central Vein Occlusion Study Group. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol. 1993;111:1087-1095.
3. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486-491.
4. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M Report. Ophthalmology. 1995;102(10):1425-1433.
5. Green WR, Chan CC, Hutchins GM, Terry JM. Central Retinal Vein Occlusion: A prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981;79:371-422.
6. Hockley DJ, Tripathi RC, Ashton N. Experimental branch vein occlusion in rhesus monkeys. III. Histopathological and electron microscopical studies. Br J Ophthalmol. 1979;63:393-411.
7. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LEH, King GL. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
8. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. J Biol Chem. 1999;274:23463-23467.
9. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor (VPF) that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
10. Vinores SA, Youssri AI, Luna JD, Chen Y-S, Bhargave S, Vinores MA, Schoenfeld C-L, Peng B, Chan CH-CH, LaRochelle W, Green WR, Campochiaro PA. Upregulation of vascular endothelial growth factor in ischemic and nonischemic human and experimental retinal disease. Histol Histopathol. 1997;12:99-109.
11. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalomology. 1998;105:412-416.
12. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71.
13. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Euro J Pharmacol. 1998;341:309-315.
14. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, Perruchoud AP. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth-factor is downregulated by corticosteroids. Am J Resp Cell Mol Biol. 1997;16:398-406.
15. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
16. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central vein occlusion. Br J Ophthalmol. 2002;86:247-248.
17. McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastamosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol. 1995;113:456-462.
18. Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina. 2001;21:408-415.
19. McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981;91:785-788.
20. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982;93:415-417.
21. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985;103:1567-1569.
22. Folkman J, Ingber DE. Angiostatic steroids. Ann Surg. 1987;206:374-383.
23. Diaz-Flores L, Gutierrez R, Varela H. Angiogenesis: an update. Histol Histopathol. 1994;9:807-843.
24. Yoshikawa K, Kotake S, Ichiishi A, Sasamoto Y, Kosaka S, Matsuda H. Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema. Jap J Ophthalmol. 1995;39:71-76.
25. Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR. A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology. 1997;104:2003-2008.
26. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90:810-816.
27. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Tr Am Ophth Soc. 1979;77:171-178.
28. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefe's Arch Clin Exp Ophthalmol. 1993;231:34-40.
29. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 1996;103:2099-2104.
30. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064-1067.
31. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol. 1995;23:293-298.
32. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor ABL, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26:277-281.
33. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
34. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-427.
35. Hee MR, Puliafito CA, Duker JS, Reichel E, Coker JG, Wilkins JR, Schuman JS, Swanson EA, Fujimoto JG. Topography of diabetic macular edema with optical coherence tomography Ophthalmology. 1998;105:360-370.
36. Baumal CR. Clinical applications of optical coherence tomography. Curr Opin Ophthalmol. 1999;10:182-188.